Pharma Patent Cliffby readouts.io
Change log · updated 28 September 2026

What changed

Every dated event that moved a loss-of-exclusivity date or changed a drug's outlook: settlements that pushed dates back, US generic and biosimilar launches, launches outside the US, and Medicare price negotiation. Follow it with the RSS feed.

  1. Outside the US
    Generic semaglutide launched in Canada

    Dr. Reddy's launched the first generic in Canada, after generics reached India in the first quarter. US protection runs to 2032. Dr. Reddy's

  2. US copies launched
    FDA approved the first US generics of Farxiga

    Several generic dapagliflozin makers were approved at once, ending US exclusivity. FDA

  3. US copies launched
    US generics of Pomalyst launched

    Breckenridge launched generic pomalidomide under the settlement timeline, with Camber following. Breckenridge

  4. Medicare price
    Trulicity, Biktarvy, Cosentyx and Entyvio selected for Medicare price negotiation

    Negotiated prices take effect in 2028. CMS must publish them by 30 November 2026. CMS

  5. Medicare price
    Medicare prices set for Ozempic, Pomalyst, Ibrance and Xtandi

    From 2027: Ozempic 71%, Pomalyst 60%, Ibrance 50% and Xtandi 48% below list price. CMS

  6. Date pushed back · 2033 → 2036
    Settlements push Biktarvy's US generic entry to April 2036

    Settlements with Lupin, Cipla and Laurus Labs bar generics before 1 April 2036, more than two years after Gilead's previous December 2033 estimate. Fierce Pharma

  7. Date pushed back · 2032 → 2037
    Settlements push Rinvoq's US generic entry to April 2037

    AbbVie settled with every generic filer. Analysts had modeled US exclusivity ending in 2032. Fierce Pharma

  8. US copies launched
    First US generics of Entresto launched

    MSN's generic launched through Novadoz, and Torrent followed two days later. Optum Rx

  9. US copies launched
    First US biosimilars of Stelara launched

    Amgen's Wezlana launched in January 2025, and several more biosimilars followed during the year. Stelara sales fell 41% in 2025. Center for Biosimilars

  10. Medicare price
    First Medicare prices set, including Eliquis, Farxiga, Entresto, Enbrel and Stelara

    From 2026: Farxiga 68%, Enbrel 67%, Stelara 66%, Eliquis 56% and Entresto 53% below list price. CMS

  11. Date pushed back · 2026 → 2032
    Takeda pushes its assumed US biosimilar entry for Entyvio to 2032

    Takeda moved its assumption from May 2026 by three to five years, citing formulation, dosing and manufacturing patents. Pharma Japan